Safety and Efficacy of Combining Metastasis-Directed Stereotactic Ablative Radiation Therapy with Tyrosine Kinase Inhibitors Versus Immune Checkpoint Inhibitors in Metastatic Hepatocellular Carcinoma

Puntos clave

• SABR treatment had a good safety profile, with rare grade 3 late adverse effects, showing its potential in treatment applications.
• Grade ≥2 late adverse effects occurred more frequently with SABR plus immune checkpoint inhibitors compared to tyrosine kinase inhibitors.
• Assessment of treatment involved comparing the efficacy of combining SABR with TKIs and ICIs in patients with extrahepatic metastatic HCC; further trials are warranted.
• These findings highlight the need for additional testing to evaluate long-term safety and efficacy in diverse populations.